Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan's Ruling Party Proposes ¥20 Billion Funding To Support Biotech Venture Companies

This article was originally published in PharmAsia News

Executive Summary

A policy team of Japan's ruling Liberal Democratic Party proposes establishing a fund to support biotech venture companies and accelerate new drug development. The ¥20 billion proposal, to be jointly funded by public and private sectors, is to select 10 companies and invest ¥2 billion in each. After the companies are profitable the fund will sell holding shares and benefit from the sales. Biotech veterans from university research facilities and pharmaceutical companies will select the candidates. (Click here for more - Japanese language) "LDP Proposes A ¥20 Billion Fund To Support Biotech Venture Companies" - Fuji Sankei Business News (6/17/08)

You may also be interested in...



QUOTED. 4 December. Eric Borin.

Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.

Pfizer’s Expected 2020 COVID-19 Vaccine Production Fell By 50% After Scaleup Delays

Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.

US FDA Expands Drug Development Tool Qualification Program With ISTAND Pilot

ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel